How is Tzield administered?
Tzield is given by intravenous infusion over a minimum of 30 minutes once daily for 14 consecutive days. Dosage is based on body surface area and increases as follows:
- Day 1: 65 mcg/m2
- Day 2: 125 mcg/m2
- Day 3: 250 mcg/m2
- Day 4: 500 mcg/m2
- Days 5 through 14: 1,030 mcg/m2.
Tzield needs to be diluted before administration and patients should be premedicated with an NSAID or acetaminophen, an antihistamine, and/or an antiemetic, approximately one hour before administration of the infusion for at least the first 5 days of the infusion.
Only one dose should be administered per day. If a dose is missed, just resume the remaining doses on consecutive days to complete the 14-day treatment course.
References
- Tzield Injection Prescribing Information. Updated 11/2022. Provention Bio, Inc. https://www.drugs.com/pro/tzield-injection.html
- FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. November 17, 2022. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes
Read next
What is Tzeild?
Tzield (teplizumab-mzwv) is an injectable medicine that is used to delay the onset of stage 3 Type 1 diabetes in people whose immune system has begun attacking their insulin-producing cells. Continue reading
How does Tzield work?
Tzield is thought to work by binding to CD3 (a cell surface antigen present on T lymphocytes) to delay the onset of stage 3 type 1 diabetes in adults and children 8 and older with stage 2 type 1 diabetes. Tzield may also deactivate the immune cells that attack insulin-producing cells while increasing the proportion of cells that help moderate the immune response. Tzield is classified as an anti-CD3 monoclonal antibody. Continue reading
How effective is Tzield?
Tzield has been shown to delay the progression of Stage 2 type 1 diabetes to Stage 3 type 1 diabetes by 25 months (approximately 2 years) in a phase 3, randomized, double-blind clinical trial. In an extended follow-up of this trial (duration 923 days), the average time to diagnosis of stage 3 type 1 diabetes was 59.6 months for Tzield-treated patients compared with 27.1 months for patients given a placebo (a difference of 32.5 months). Continue reading
Related medical questions
- What foods should I eat or avoid for hypoglycemia?
- Can you have hypoglycemia without diabetes?
- Which type of insulin has the longest duration of action?
- Basaglar and Lantus - What is the difference between them?
- When should I take Lantus?
- Levemir vs Lantus: What's the difference?
- Does Lantus insulin need to be refrigerated?
- Toujeo vs Lantus - What's the difference between them?
- What is the difference between regular insulin and lispro (Humalog)?
- Humalog vs Novolog (Novalog): What's the difference?
- Are Humulin and Humalog the same thing?
- How long does Lantus last?
- How to test for hypoglycemia at home?
- Are glucagon and glycogen the same thing?
- Toujeo vs Tresiba - What's the difference between them?
- Is Tresiba the same as Lantus?
- How do beta-blockers mask hypoglycemia?
- Humulin N vs Humulin R - What's the difference?
- Is Novolin the same as Humulin?
- When is the best time to take Toujeo?
- How do you use the Lantus pen (Lantus SoloStar)?
- How long can Toujeo stay out of the refrigerator?
- How long can Tresiba be out of the fridge?
- What are the different types of insulin?
- When does insulin lispro peak / how long does it last?
- Can you take Tresiba twice a day?
- How much Toujeo is too much?
- Soliqua vs Lantus: What’s the difference between them?
- How long can Humulin be unrefrigerated?
- What is the difference between Fiasp and NovoLog?
Drug information
Related support groups
- Teplizumab (4 questions, 3 members)
- Tzield (4 questions, 3 members)
- Diabetes, Type 1 (81 questions, 143 members)